🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Italy / NCT07717671
Starting soon Not applicable

VIPPSTAR-G1 Digital Early Intervention for Visual Impairment

NCT07717671 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2026-07-01
Last updated
2026-07-21

Condition(s) studied

Visual ImpairmentCerebral Visual ImpairmentNeurodevelopmental DisordersPrematurity

Investigational drug(s) / intervention(s)

VIPPSTAR Digital Early InterventionStandard Clinical Care

VIPPSTAR Digital Early Intervention: A caregiver-mediated digital intervention aimed at promoting visual and neurodevelopmental outcomes in infants at risk of or with visual impairment, within a framework that promotes and strengthens the parent-child/caregiver-child relationship. The intervention includes individualized activities integrated into daily family routines and supported through remote supervision and e-learning content.

Standard Clinical Care: Routine clinical care provided according to local healthcare protocols, including follow-up visits and additional evaluations if clinically indicated.Standard intervention protocols according to local healthcare services are allowed.

Study summary

Visual impairment in infancy is associated with significant risks for neurodevelopmental impairment. Early intervention based on enriched visual and multisensory experiences may promote neuroplasticity and improve developmental outcomes, but implementation of intensive interventions in routine clinical practice remains challenging. The VIPPSTAR-G1 study evaluates a caregiver-mediated digital intervention delivered through a dedicated platform designed to support visual and neurodevelopmental functions in infants at risk of or with visual impairment, within a framework that promotes and strengthens the parent-child/caregiver-child relationship.

This multicenter, multinational, single-blind randomized controlled trial will enroll 102 newborns at risk of visual impairment and an additional exploratory pilot subgroup of 48 infants and toddlers with established visual impairment. Participants will be randomized to receive either the VIPPSTAR digital intervention plus standard care or standard care alone. Outcomes include visual acuity, smooth pursuit, additional neuro-ophthalmological functions, neurodevelopmental measures, adaptive functioning, language development, parental stress, quality of life, and feasibility of the digital intervention.

Eligibility

Sex
ALL
Min age
1 Day
Max age
42 Months
Healthy volunteers
No
Inclusion Criteria: Study Sample 1 - Infants at Risk of Visual Impairment * Gestational age ≤32 weeks OR full-term/newborns\>32 weeks of age with neonatal distress (Apgar ≤5 at 10 minutes) * NAVEG score ≥3 * At least one neurological or neuroimaging abnormality: * 3 abnormal signs at ATNAT neurological examination OR Abnormal cranial ultrasound findings OR Abnormal MRI findings Exclusion Criteria: Study Sample 1 - Infants at Risk of Visual Impairment * Epileptic encephalopathy * Parents unable to understand local language Inclusion Criteria: Study Sample 2 - Infants/Toddlers With Visual Impairment * Age ≤42 months * Diagnosis of peripheral or cerebral visual impairment * Moderate or severe visual impairment documented by standardized visual acuity testing Exclusion Criteria: Study Sample 2 - Infants/Toddlers With Visual Impairment * Age \>42 months * Refractory epilepsy or epileptic encephalopathy * Participation in another interventional study within previous 12 months * Parents unable to understand local language

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Katholieke Universiteit Leuven Leuven Belgium
ASST Spedali Civili di Brescia Brescia BS
University of Brescia Brescia BS
Department of Brain and Behavioral Sciences University of Pavia - Child Neurology and Psychiatry Unit IRCCS Mondino Foundation Pavia BS
Centrul Republican de Reabilitare pentru Copii Chisinau Moldova

More Università degli Studi di Brescia trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07717671 on ClinicalTrials.gov ↗ ← All trials in Italy